CoChat

Treatment of Pseudomonas aeruginosa infectious biofilms: Challenges and strategies

Yin, Rui, Cheng, Juanli, Wang, Jingyao, Li, Panxin, Lin, Jinshui · 2022 · Frontiers in Microbiology
Cited by 151

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Pseudomonas aeruginosa , a Gram-negative bacterium, is one of the major pathogens implicated in human opportunistic infection and a common cause of clinically persistent infections such as cystic fibrosis, urinary tract infections, and burn infections. The main reason for the persistence of P. aeruginosa infections is due to the ability of P. aeruginosa to secrete extracellular polymeric substances such as exopolysaccharides, matrix proteins, and extracellular DNA during invasion. These substances adhere to and wrap around bacterial cells to form a biofilm. Biofilm formation leads to multiple antibiotic resistance in P. aeruginosa , posing a significant challenge to conventional single antibiotic therapeutic approaches. It has therefore become particularly important to develop anti-biofilm drugs. In recent years, a number of new alternative drugs have been developed to treat P. aeruginosa infectious biofilms, including antimicrobial peptides, quorum-sensing inhibitors, bacteriophage therapy, and antimicrobial photodynamic therapy. This article briefly introduces the process and regulation of P. aeruginosa biofilm formation and reviews several developed anti-biofilm treatment technologies to provide new directions for the treatment of P. aeruginosa biofilm infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fmicb.2022.955286

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 185

  1. Abdi, 2019, Bacterial resistance to antimicrobial peptides, J. Pept. Sci., 25, e3210, 10.1002/psc.3210 · DOI
  2. Abedon, 2021, Improving phage-biofilm in vitro experimentation, Viruses, 13, 1175, 10.3390/v13061175 · DOI
  3. Abedon, 2011, Phage treatment of human infections, Bacteriophage, 1, 66, 10.4161/bact.1.2.15845 · DOI · Paper page
  4. Ahmed, 2019, Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors, Appl. Microbiol. Biotechnol., 103, 3521, 10.1007/s00253-019-09618-0 · DOI · Paper page
  5. Al-Bakri, 2019, Photothermal-induced antibacterial activity of gold nanorods loaded into polymeric hydrogel against Pseudomonas aeruginosa biofilm, Molecules, 24, 2661, 10.3390/molecules24142661 · DOI
  6. Al-Dahmoshi, 2021, Pseudomonas aeruginosa: diseases, biofilm and antibiotic resistance
  7. Allesen-Holm, 2006, A characterization of DNA release in Pseudomonas aeruginosa cultures and biofilms, Mol. Microbiol., 59, 1114, 10.1111/j.1365-2958.2005.05008.x · DOI · Paper page
  8. Annunziato, 2020, Antimicrobial peptides (AMPs): A patent review (2015-2020), Expert Opin. Ther. Pat., 30, 931, 10.1080/13543776.2020.1851679 · DOI
  9. Martins Antunes de Melo, 2021, Antimicrobial photodynamic therapy (aPDT) for biofilm treatments. Possible synergy between aPDT and pulsed electric fields, Virulence, 12, 2247, 10.1080/21505594.2021.1960105 · DOI
  10. Aoki, 2013, Characterization of antimicrobial peptides toward the development of novel antibiotics, Pharmaceuticals (Basel), 6, 1055, 10.3390/ph6081055 · DOI · Paper page
  11. Azam, 2019, Updates on the pathogenicity status of Pseudomonas aeruginosa, Drug Discov. Today, 24, 350, 10.1016/j.drudis.2018.07.003 · DOI · Paper page
  12. Baker, 2016, Exopolysaccharide biosynthetic glycoside hydrolases can be utilized to disrupt and prevent Pseudomonas aeruginosa biofilms, Sci. Adv., 2, e1501632, 10.1126/sciadv.1501632 · DOI · Paper page
  13. Bala, 2015, Augmentation of virulence related traits of pqs mutants by pseudomonas quinolone signal through membrane vesicles, J. Basic Microbiol., 55, 566, 10.1002/jobm.201400377 · DOI
  14. Banin, 2008, The potential of desferrioxamine-gallium as an anti-pseudomonas therapeutic agent, Proc. Natl. Acad. Sci. U. S. A., 105, 16761, 10.1073/pnas.0808608105 · DOI · Paper page
  15. Barraud, 2006, Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa, J. Bacteriol., 188, 7344, 10.1128/JB.00779-06 · DOI · Paper page
  16. Barraud, 2012, Cephalosporin-3'-diazeniumdiolates: targeted NO-donor prodrugs for dispersing bacterial biofilms, Angew. Chem. Int. Ed. Engl., 51, 9057, 10.1002/anie.201202414 · DOI · Paper page
  17. Beaudoin, 2018, Activity of a novel antimicrobial peptide against Pseudomonas aeruginosa biofilms, Sci. Rep., 8, 14728, 10.1038/s41598-018-33016-7 · DOI
  18. Beirao, 2014, Photodynamic inactivation of bacterial and yeast biofilms with a cationic porphyrin, Photochem. Photobiol., 90, 1387, 10.1111/php.12331 · DOI
  19. Bilici, 2020, Broad spectrum antibacterial photodynamic and photothermal therapy achieved with indocyanine green loaded SPIONs under near infrared irradiation, Biomater. Sci., 8, 4616, 10.1039/d0bm00821d · DOI
  20. Bonchi, 2015, Pyoverdine and proteases affect the response of Pseudomonas aeruginosa to gallium in human serum, Antimicrob. Agents Chemother., 59, 5641, 10.1128/AAC.01097-15 · DOI
  21. Byrd, 2009, Genetic and biochemical analyses of the Pseudomonas aeruginosa Psl exopolysaccharide reveal overlapping roles for polysaccharide synthesis enzymes in Psl and LPS production, Mol. Microbiol., 73, 622, 10.1111/j.1365-2958.2009.06795.x · DOI · Paper page
  22. Chanda, 2017, Combined effect of linolenic acid and tobramycin on Pseudomonas aeruginosa biofilm formation and quorum sensing, Exp. Ther. Med., 14, 4328, 10.3892/etm.2017.5110 · DOI
  23. Chang, 2019, Design, synthesis and evaluation of halogenated furanone derivatives as quorum sensing inhibitors in Pseudomonas aeruginosa, Eur. J. Pharm. Sci., 140, 105058, 10.1016/j.ejps.2019.105058 · DOI
  24. Chauhan, 2012, Full and broad-spectrum in vivo eradication of catheter-associated biofilms using gentamicin-EDTA antibiotic lock therapy, Antimicrob. Agents Chemother., 56, 6310, 10.1128/AAC.01606-12 · DOI
  25. Chegini, 2020, Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review, Ann. Clin. Microbiol. Antimicrob., 19, 45, 10.1186/s12941-020-00389-5 · DOI · Paper page
  26. Chou, 2019, Short, symmetric-helical peptides have narrow-spectrum activity with low resistance potential and high selectivity, Biomater. Sci., 7, 2394, 10.1039/c9bm00044e · DOI
  27. Chrzanowski, 2012, Why do microorganisms produce rhamnolipids?, World J. Microbiol. Biotechnol., 28, 401, 10.1007/s11274-011-0854-8 · DOI · Paper page
  28. Clokie, 2011, Phages in nature, Bacteriophage, 1, 31, 10.4161/bact.1.1.14942 · DOI · Paper page
  29. Colvin, 2013, PelA deacetylase activity is required for Pel polysaccharide synthesis in Pseudomonas aeruginosa, J. Bacteriol., 195, 2329, 10.1128/JB.02150-12 · DOI · Paper page
  30. Colvin, 2011, The pel polysaccharide can serve a structural and protective role in the biofilm matrix of Pseudomonas aeruginosa, PLoS Pathog., 7, e1001264, 10.1371/journal.ppat.1001264 · DOI · Paper page
  31. Colvin, 2012, The Pel and Psl polysaccharides provide Pseudomonas aeruginosa structural redundancy within the biofilm matrix, Environ. Microbiol., 14, 1913, 10.1111/j.1462-2920.2011.02657.x · DOI · Paper page
  32. Costerton, 1999, Bacterial biofilms: A common cause of persistent infections, Science, 284, 1318, 10.1126/science.284.5418.1318 · DOI · Paper page
  33. Cutruzzola, 2016, Origin and impact of nitric oxide in Pseudomonas aeruginosa biofilms, J. Bacteriol., 198, 55, 10.1128/JB.00371-15 · DOI · Paper page
  34. Daboor, 2021, Disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate lyase enhances pathogen eradication by antibiotics, J. Cyst. Fibros., 20, 264, 10.1016/j.jcf.2020.04.006 · DOI
  35. Das, 2020, Pseudomonas aeruginosa biofilms and infections: roles of extracellular molecules,, 29, 10.1016/B978-0-444-64279-0.00003-7 · DOI
  36. Davey, 2003, Rhamnolipid surfactant production affects biofilm architecture in Pseudomonas aeruginosa PAO1, J. Bacteriol., 185, 1027, 10.1128/JB.185.3.1027-1036.2003 · DOI · Paper page
  37. de la Fuente-Nunez, 2012, Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide, Antimicrob. Agents Chemother., 56, 2696, 10.1128/AAC.00064-12 · DOI · Paper page
  38. Di, 2020, Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria, Sci. Adv., 6, eaay6817, 10.1126/sciadv.aay6817 · DOI
  39. Donlan, 2002, Biofilms: microbial life on surfaces, Emerg. Infect. Dis., 8, 881, 10.3201/eid0809.020063 · DOI · Paper page
  40. Dosselli, 2012, Molecular targets of antimicrobial photodynamic therapy identified by a proteomic approach, J. Proteome, 77, 329, 10.1016/j.jprot.2012.09.007 · DOI
  41. Drenkard, 2003, Antimicrobial resistance of Pseudomonas aeruginosa biofilms, Microbes Infect., 5, 1213, 10.1016/j.micinf.2003.08.009 · DOI · Paper page
  42. Dufour, 2010, Bacterial biofilm: structure, function, and antimicrobial resistance, Endod. Top., 22, 2, 10.1111/j.1601-1546.2012.00277.x · DOI · Paper page
  43. Eckhart, 2007, DNase1L2 suppresses biofilm formation by Pseudomonas aeruginosa and Staphylococcus aureus, Br. J. Dermatol., 156, 1342, 10.1111/j.1365-2133.2007.07886.x · DOI · Paper page
  44. Elmanama, 2020, Antimicrobial resistance and biofilm formation of Pseudomonas aeruginosa, Int. Arabic J. Antimicrob. Agents, 10, 3, 10.3823/846 · DOI
  45. Epstein, 2012, Liquid-infused structured surfaces with exceptional anti-biofouling performance, Proc. Natl. Acad. Sci. U. S. A., 109, 13182, 10.1073/pnas.1201973109 · DOI · Paper page
  46. Feng, 2021, Photodynamic and antibiotic therapy in combination against bacterial infections: efficacy, determinants, mechanisms, and future perspectives, Adv. Drug Deliv. Rev., 177, 113941, 10.1016/j.addr.2021.113941 · DOI · Paper page
  47. Feng, 2015, Functional synergy of alpha-helical antimicrobial peptides and traditional antibiotics against gram-negative and gram-positive bacteria in vitro and in vivo, Eur. J. Clin. Microbiol. Infect. Dis., 34, 197, 10.1007/s10096-014-2219-3 · DOI
  48. Ferriol-Gonzalez, 2020, Phages for biofilm removal, Antibiotics (Basel), 9, 268, 10.3390/antibiotics9050268 · DOI · Paper page
  49. Finkel, 2001, DNA as a nutrient: novel role for bacterial competence gene homologs, J. Bacteriol., 183, 6288, 10.1128/JB.183.21.6288-6293.2001 · DOI · Paper page
  50. Fleming, 2017, Glycoside hydrolases degrade polymicrobial bacterial biofilms in wounds, Antimicrob. Agents Chemother., 61, e01998-16, 10.1128/AAC.01998-16 · DOI · Paper page
  51. Franklin, 2011, Biosynthesis of the Pseudomonas aeruginosa extracellular polysaccharides, alginate, Pel, and Psl, Front. Microbiol., 2, 167, 10.3389/fmicb.2011.00167 · DOI · Paper page
  52. Ghafoor, 2011, Role of exopolysaccharides in Pseudomonas aeruginosa biofilm formation and architecture, Appl. Environ. Microbiol., 77, 5238, 10.1128/AEM.00637-11 · DOI · Paper page
  53. Ghorbani, 2017, In vitro synergy of antibiotic combinations against planktonic and biofilm Pseudomonas aeruginosa, GMS Hyg. Infect. Control., 12, Doc17, 10.3205/dgkh000302 · DOI
  54. Gnanadhas, 2015, Chronic lung infection by Pseudomonas aeruginosa biofilm is cured by L-methionine in combination with antibiotic therapy, Sci. Rep., 5, 16043, 10.1038/srep16043 · DOI
  55. Goss, 2018, Gallium disrupts bacterial iron metabolism and has therapeutic effects in mice and humans with lung infections, Sci. Transl. Med., 10, eaat7520, 10.1126/scitranslmed.aat7520 · DOI · Paper page
  56. Harper, 2014, Bacteriophages and Biofilms, Antibiotics, 3, 270, 10.3390/antibiotics3030270 · DOI · Paper page
  57. Hoiby, 2010, Antibiotic resistance of bacterial biofilms, Int. J. Antimicrob. Agents, 35, 322, 10.1016/j.ijantimicag.2009.12.011 · DOI · Paper page
  58. Hoiby, 2011, The clinical impact of bacterial biofilms, Int. J. Oral Sci., 3, 55, 10.4248/IJOS11026 · DOI · Paper page
  59. Hossain, 2017, Discovery of a novel nitric oxide binding protein and nitric-oxide-responsive signaling pathway in Pseudomonas aeruginosa, ACS Infect. Dis., 3, 454, 10.1021/acsinfecdis.7b00027 · DOI
  60. Howlin, 2017, Low-dose nitric oxide as targeted anti-biofilm adjunctive therapy to treat chronic Pseudomonas aeruginosa infection in cystic fibrosis, Mol. Ther., 25, 2104, 10.1016/j.ymthe.2017.06.021 · DOI · Paper page
  61. Hu, 2018, Antimicrobial photodynamic therapy to control clinically relevant biofilm infections, Front. Microbiol., 9, 1299, 10.3389/fmicb.2018.01299 · DOI · Paper page
  62. Huang, 2019, An integrated genomic regulatory network of virulence-related transcriptional factors in Pseudomonas aeruginosa, Nat. Commun., 10, 2931, 10.1038/s41467-019-10778-w · DOI · Paper page
  63. Hughes, 2017, Novel approaches to the treatment of bacterial biofilm infections, Br. J. Pharmacol., 174, 2237, 10.1111/bph.13706 · DOI · Paper page
  64. Jamal, 2018, Bacterial biofilm and associated infections, J. Chin. Med. Assoc., 81, 7, 10.1016/j.jcma.2017.07.012 · DOI · Paper page
  65. Jennings, 2015, Pel is a cationic exopolysaccharide that cross-links extracellular DNA in the Pseudomonas aeruginosa biofilm matrix, Proc. Natl. Acad. Sci. U. S. A., 112, 11353, 10.1073/pnas.1503058112 · DOI · Paper page
  66. Jiang, 2020, Targeting biofilms therapy: current research strategies and development hurdles, Microorganisms, 8, 1222, 10.3390/microorganisms8081222 · DOI · Paper page
  67. Kalia, 2013, Quorum sensing inhibitors: An overview, Biotechnol. Adv., 31, 224, 10.1016/j.biotechadv.2012.10.004 · DOI · Paper page
  68. Kamal, 2017, Quorum sensing inhibitors as pathoblockers for Pseudomonas aeruginosa infections: A new concept in anti-infective drug discovery,, 185
  69. Kamaruzzaman, 2018, Targeting the bacterial protective armour; challenges and novel strategies in the treatment of microbial biofilm, Materials (Basel), 11, 1705, 10.3390/ma11091705 · DOI · Paper page
  70. Kaneko, 2007, The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity, J. Clin. Invest., 117, 877, 10.1172/JCI30783 · DOI · Paper page
  71. Kang, 2021, Pyoverdine inhibitors and gallium nitrate synergistically affect Pseudomonas aeruginosa, mSphere, 6, e0040121, 10.1128/mSphere.00401-21 · DOI
  72. Khan, 2020, Alternative strategies for the application of aminoglycoside antibiotics against the biofilm-forming human pathogenic bacteria, Appl. Microbiol. Biotechnol., 104, 1955, 10.1007/s00253-020-10360-1 · DOI
  73. Kim, 2016, Biofilm dispersion in Pseudomonas aeruginosa, J. Microbiol., 54, 71, 10.1007/s12275-016-5528-7 · DOI
  74. Kitao, 2018, Molecular insights into function and competitive inhibition of Pseudomonas aeruginosa multiple virulence factor regulator, mBio, 9, e02158-17, 10.1128/mBio.02158-17 · DOI
  75. Koo, 2017, Targeting microbial biofilms: current and prospective therapeutic strategies, Nat. Rev. Microbiol., 15, 740, 10.1038/nrmicro.2017.99 · DOI · Paper page
  76. Kostakioti, 2013, Bacterial biofilms: development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era, Cold Spring Harb. Perspect. Med., 3, a010306, 10.1101/cshperspect.a010306 · DOI · Paper page
  77. Kovach, 2020, Specific disruption of established Pseudomonas aeruginosa biofilms using polymer-attacking enzymes, Langmuir, 36, 1585, 10.1021/acs.langmuir.9b02188 · DOI
  78. Kumar, 2017, Biofilms: survival and defense strategy for pathogens, Int. J. Med. Microbiol., 307, 481, 10.1016/j.ijmm.2017.09.016 · DOI · Paper page
  79. Kumar, 2013, Zingerone inhibit biofilm formation and improve antibiofilm efficacy of ciprofloxacin against Pseudomonas aeruginosa PAO1, Fitoterapia, 90, 73, 10.1016/j.fitote.2013.06.017 · doi:10.1016/j.fitote.2013.06.017
  80. Kumar, 2015, Zingerone silences quorum sensing and attenuates virulence of Pseudomonas aeruginosa, Fitoterapia, 102, 84, 10.1016/j.fitote.2015.02.002 · DOI
  81. Kutateladze, 2010, Bacteriophages as potential new therapeutics to replace or supplement antibiotics, Trends Biotechnol., 28, 591, 10.1016/j.tibtech.2010.08.001 · DOI · Paper page
  82. Kutter, 2010, Phage therapy in clinical practice: treatment of human infections, Curr. Pharm. Biotechnol., 11, 69, 10.2174/138920110790725401 · DOI · Paper page
  83. Lashua, 2016, Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells, J. Antimicrob. Chemother., 71, 2200, 10.1093/jac/dkw143 · DOI
  84. Le, 2017, Intracellular targeting mechanisms by antimicrobial peptides, Antimicrob. Agents Chemother., 61, e02340-16, 10.1128/AAC.02340-16 · DOI · Paper page
  85. Lebeaux, 2015, In vitro activity of gentamicin, vancomycin or amikacin combined with EDTA or l-arginine as lock therapy against a wide spectrum of biofilm-forming clinical strains isolated from catheter-related infections, J. Antimicrob. Chemother., 70, 1704, 10.1093/jac/dkv044 · DOI
  86. Lee, 2017, Pseudomonas aeruginosa biofilm, a programmed bacterial life for fitness, J. Microbiol. Biotechnol., 27, 1053, 10.4014/jmb.1611.11056 · DOI · Paper page
  87. Lee, 2015, The hierarchy quorum sensing network in Pseudomonas aeruginosa, Protein Cell, 6, 26, 10.1007/s13238-014-0100-x · DOI · Paper page
  88. Lequette, 2005, Timing and localization of rhamnolipid synthesis gene expression in Pseudomonas aeruginosa biofilms, J. Bacteriol., 187, 37, 10.1128/JB.187.1.37-44.2005 · DOI · Paper page
  89. Li, 2019, Near-infrared light-enhanced protease-conjugated gold nanorods as a photothermal antimicrobial agent for elimination of exotoxin and biofilms, Int. J. Nanomedicine, 14, 8047, 10.2147/IJN.S212750 · DOI
  90. Li, 2020, Mechanisms and control measures of mature biofilm resistance to antimicrobial agents in the clinical context, ACS Omega, 5, 22684, 10.1021/acsomega.0c02294 · DOI
  91. Liang, 2020, Effect of antibacterial photodynamic therapy on Streptococcus mutans plaque biofilm in vitro, J. Innov. Opt. Health Sci., 13, 2050022, 10.1142/S1793545820500224 · DOI
  92. Lichtenberg, 2022, The structure-function relationship of Pseudomonas aeruginosa in infections and its influence on the microenvironment, FEMS Microbiol. Rev., 10.1093/femsre/fuac018 · DOI · Paper page
  93. Limoli, 2015, Bacterial extracellular polysaccharides in biofilm formation and function, Microbiol. Spectr., 3, MB-0011, 10.1128/microbiolspec.MB-0011-2014 · DOI · Paper page
  94. Limoli, 2014, Cationic antimicrobial peptides promote microbial mutagenesis and pathoadaptation in chronic infections, PLoS Pathog., 10, e1004083, 10.1371/journal.ppat.1004083 · DOI · Paper page
  95. Lin, 2019, Quorum sensing in Pseudomonas aeruginosa and its relationship to biofilm development,, 1, 10.1021/bk-2019-1323.ch001 · DOI
  96. Lin, The pseudomonas quinolone signal (PQS): not just for quorum sensing anymore, Front. Cell. Infect. Microbiol., 8, 230, 10.3389/fcimb.2018.00230 · DOI · Paper page
  97. Lin, Prevention of ESKAPE pathogen biofilm formation by antimicrobial peptides WLBU2 and LL37, Int. J. Antimicrob. Agents, 52, 667, 10.1016/j.ijantimicag.2018.04.019 · DOI
  98. Lin, 2021, Acidic microenvironment determines antibiotic susceptibility and biofilm formation of Pseudomonas aeruginosa, Front. Microbiol., 12, 747834, 10.3389/fmicb.2021.747834 · DOI
  99. Llamas, 2006, The heterologous siderophores ferrioxamine B and ferrichrome activate signaling pathways in Pseudomonas aeruginosa, J. Bacteriol., 188, 1882, 10.1128/JB.188.5.1882-1891.2006 · DOI · Paper page
  100. Ma, 2009, Assembly and development of the Pseudomonas aeruginosa biofilm matrix, PLoS Pathog., 5, e1000354, 10.1371/journal.ppat.1000354 · DOI · Paper page
  101. Ma, 2006, Analysis of Pseudomonas aeruginosa conditional Psl variants reveals roles for the Psl polysaccharide in adhesion and maintaining biofilm structure postattachment, J. Bacteriol., 188, 8213, 10.1128/JB.01202-06 · DOI · Paper page
  102. Ma, 2022, Regulation of biofilm exopolysaccharide biosynthesis and degradation in Pseudomonas aeruginosa, Annu. Rev. Microbiol., 76, 413, 10.1146/annurev-micro-041320-111355 · DOI
  103. Ma, 2012, The roles of biofilm matrix polysaccharide Psl in mucoid Pseudomonas aeruginosa biofilms, FEMS Immunol. Med. Microbiol., 65, 377, 10.1111/j.1574-695X.2012.00934.x · DOI · Paper page
  104. Mahlapuu, 2016, Antimicrobial peptides: An emerging category of therapeutic agents, Front. Cell. Infect. Microbiol., 6, 194, 10.3389/fcimb.2016.00194 · DOI · Paper page
  105. Mann, 2012, Pseudomonas biofilm matrix composition and niche biology, FEMS Microbiol. Rev., 36, 893, 10.1111/j.1574-6976.2011.00322.x · DOI · Paper page
  106. Marmont, 2017, PelA and PelB proteins form a modification and secretion complex essential for Pel polysaccharide-dependent biofilm formation in Pseudomonas aeruginosa, J. Biol. Chem., 292, 19411, 10.1074/jbc.M117.812842 · DOI
  107. Marshall, 2009, Citrate-mediated iron uptake in Pseudomonas aeruginosa: involvement of the citrate-inducible FecA receptor and the FeoB ferrous iron transporter, Microbiology (Reading), 155, 305, 10.1099/mic.0.023531-0 · DOI · Paper page
  108. Martinez, 2019, Synergistic and antibiofilm activity of the antimicrobial peptide P5 against carbapenem-resistant Pseudomonas aeruginosa, Biochim. Biophys. Acta Biomembr., 1861, 1329, 10.1016/j.bbamem.2019.05.008 · DOI
  109. Maura, 2017, Pharmacological inhibition of the Pseudomonas aeruginosa MvfR quorum-sensing system interferes with biofilm formation and potentiates antibiotic-mediated biofilm disruption, Antimicrob. Agents Chemother., 61, e01362-17, 10.1128/AAC.01362-17 · DOI
  110. Maurice, 2018, Pseudomonas aeruginosa biofilms: Host response and clinical implications in lung infections, Am. J. Respir. Cell Mol. Biol., 58, 428, 10.1165/rcmb.2017-0321TR · DOI · Paper page
  111. Melo, 2019, Phage therapy of infectious biofilms: challenges and strategies,, 295, 10.1007/978-3-030-26736-0_11 · DOI
  112. Mi, 2019, Identification of a lytic Pseudomonas aeruginosa phage depolymerase and its anti-biofilm effect and bactericidal contribution to serum, Virus Genes, 55, 394, 10.1007/s11262-019-01660-4 · DOI
  113. Minandri, 2014, Promises and failures of gallium as an antibacterial agent, Future Microbiol., 9, 379, 10.2217/fmb.14.3 · DOI
  114. Mitchell, 2016, Fungal super glue: the biofilm matrix and its composition, assembly, and functions, PLoS Pathog., 12, e1005828, 10.1371/journal.ppat.1005828 · DOI · Paper page
  115. Moradali, 2017, Pseudomonas aeruginosa lifestyle: A paradigm for adaptation, survival, and persistence, Front. Cell. Infect. Microbiol., 7, 39, 10.3389/fcimb.2017.00039 · DOI · Paper page
  116. Moradali, 2019, The role of alginate in bacterial biofilm formation,, 517, 10.1007/978-3-030-12919-4_13 · DOI
  117. Muhlen, 2016, Anti-virulence strategies to target bacterial infections, Curr. Top. Microbiol. Immunol., 398, 147, 10.1007/82_2015_490 · DOI · Paper page
  118. O'Brien, 2015, Potent irreversible inhibitors of LasR quorum sensing in Pseudomonas aeruginosa, ACS Med. Chem. Lett., 6, 162, 10.1021/ml500459f · DOI
  119. Olivares, 2019, Clinical impact of antibiotics for the treatment of Pseudomonas aeruginosa biofilm infections, Front. Microbiol., 10, 2894, 10.3389/fmicb.2019.02894 · DOI · Paper page
  120. Overhage, 2008, Human host defense peptide LL-37 prevents bacterial biofilm formation, Infect. Immun., 76, 4176, 10.1128/IAI.00318-08 · DOI · Paper page
  121. Pang, 2019, Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies, Biotechnol. Adv., 37, 177, 10.1016/j.biotechadv.2018.11.013 · DOI · Paper page
  122. Pang, 2021, Traditional Chinese medicine is an alternative therapeutic option for treatment of Pseudomonas aeruginosa infections, Front. Pharmacol., 12, 737252, 10.3389/fphar.2021.737252 · DOI
  123. Pei, 2014, Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes, Appl. Environ. Microbiol., 80, 5340, 10.1128/AEM.01434-14 · DOI · Paper page
  124. Perez-Laguna, 2020, Photodynamic therapy using methylene blue, combined or not with gentamicin, against Staphylococcus aureus and Pseudomonas aeruginosa, Photodiagn. Photodyn. Ther., 31, 101810, 10.1016/j.pdpdt.2020.101810 · DOI
  125. Pires, 2016, Bacteriophage-encoded depolymerases: their diversity and biotechnological applications, Appl. Microbiol. Biotechnol., 100, 2141, 10.1007/s00253-015-7247-0 · DOI · Paper page
  126. Poh, 2022, Recent developments in nitric oxide donors and delivery for antimicrobial and anti-biofilm applications, Molecules, 27, 674, 10.3390/molecules27030674 · DOI · Paper page
  127. Pontes, 2022, Antimicrobial peptides as an alternative for the eradication of bacterial biofilms of multi-drug resistant bacteria, Pharmaceutics, 14, 642, 10.3390/pharmaceutics14030642 · DOI
  128. Qi, 2019, Role of flagella, type IV Pili, biosurfactants, and extracellular polymeric substance polysaccharides on the formation of pellicles by Pseudomonas aeruginosa, Langmuir, 35, 5294, 10.1021/acs.langmuir.9b00271 · DOI
  129. Qin, 2009, Pseudomonas aeruginosa extracellular products inhibit staphylococcal growth, and disrupt established biofilms produced by Staphylococcus epidermidis, Microbiology (Reading), 155, 2148, 10.1099/mic.0.028001-0 · DOI · Paper page
  130. Rahmani-Badi, 2014, A combination of cis-2-decenoic acid and antibiotics eradicates pre-established catheter-associated biofilms, J. Med. Microbiol., 63, 1509, 10.1099/jmm.0.075374-0 · DOI
  131. Rajesh, 2011, Antimicrobial photodynamic therapy: An overview, J. Indian Soc. Periodontol., 15, 323, 10.4103/0972-124X.92563 · DOI
  132. Rajkumari, 2018, Cinnamic acid attenuates quorum sensing associated virulence factors and biofilm formation in Pseudomonas aeruginosa PAO1, Biotechnol. Lett., 40, 1087, 10.1007/s10529-018-2557-9 · DOI
  133. Redman, 2020, Differential efficacy of glycoside hydrolases to disperse biofilms, Front. Cell. Infect. Microbiol., 10, 379, 10.3389/fcimb.2020.00379 · DOI
  134. Roy, 2018, Strategies for combating bacterial biofilms: A focus on anti-biofilm agents and their mechanisms of action, Virulence, 9, 522, 10.1080/21505594.2017.1313372 · DOI · Paper page
  135. Rumbaugh, 2020, Biofilm dispersion, Nat. Rev. Microbiol., 18, 571, 10.1038/s41579-020-0385-0 · DOI · Paper page
  136. Rutherford, 2012, Bacterial quorum sensing: its role in virulence and possibilities for its control, Cold Spring Harb. Perspect. Med., 2, a012427, 10.1101/cshperspect.a012427 · DOI · Paper page
  137. Rzhepishevska, 2011, The antibacterial activity of Ga3+ is influenced by ligand complexation as well as the bacterial carbon source, Antimicrob. Agents Chemother., 55, 5568, 10.1128/AAC.00386-11 · DOI
  138. Schmelcher, 2012, Bacteriophage endolysins as novel antimicrobials, Future Microbiol., 7, 1147, 10.2217/fmb.12.97 · DOI · Paper page
  139. Schutz, 2018, Targeting the pseudomonas quinolone signal quorum sensing system for the discovery of novel anti-infective pathoblockers, Beilstein J. Org. Chem., 14, 2627, 10.3762/bjoc.14.241 · DOI
  140. Schutz, 2021, A new PqsR inverse agonist potentiates tobramycin efficacy to eradicate Pseudomonas aeruginosa biofilms, Adv. Sci. (Weinh), 8, e2004369, 10.1002/advs.202004369 · DOI
  141. Seyfi, 2020, Antimicrobial peptides (AMPs): roles, functions and mechanism of action, Int. J. Pept. Res. Ther., 26, 1451, 10.1007/s10989-019-09946-9 · DOI · Paper page
  142. Shao, 2020, Novel therapeutic strategies for treating Pseudomonas aeruginosa infection, Expert Opin. Drug Discov., 15, 1403, 10.1080/17460441.2020.1803274 · DOI
  143. Sharma, 2019, Antibiotics versus biofilm: An emerging battleground in microbial communities, Antimicrob. Resist. Infect. Control, 8, 76, 10.1186/s13756-019-0533-3 · DOI · Paper page
  144. Sharma, 2018, Antibiofilm effect of DNase against single and mixed species biofilm, Foods, 7, 42, 10.3390/foods7030042 · DOI
  145. Shrestha, 2022, Recent strategies to combat biofilms using antimicrobial agents and therapeutic approaches, Pathogens, 11, 292, 10.3390/pathogens11030292 · DOI
  146. Shrivastava, 2018, World health organization releases global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics, J. Med. Soc., 32, 76, 10.4103/jms.jms_25_17 · DOI · Paper page
  147. Smith, 2017, Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis, FEMS Microbiol. Lett., 364, fnx121, 10.1093/femsle/fnx121 · DOI
  148. Soothill, 2013, Use of bacteriophages in the treatment of Pseudomonas aeruginosa infections, Expert Rev. Anti Infect. Ther., 11, 909, 10.1586/14787210.2013.826990 · DOI
  149. Soren, 2020, Cephalosporin nitric oxide-donor prodrug DEA-C3D disperses biofilms formed by clinical cystic fibrosis isolates of Pseudomonas aeruginosa, J. Antimicrob. Chemother., 75, 117, 10.1093/jac/dkz378 · DOI
  150. Soukarieh, 2018, Pseudomonas aeruginosa quorum sensing systems as drug discovery targets: current position and future perspectives, J. Med. Chem., 61, 10385, 10.1021/acs.jmedchem.8b00540 · DOI
  151. Srinivasan, 2021, Bacterial biofilm inhibition: A focused review on recent therapeutic strategies for combating the biofilm mediated infections, Front. Microbiol., 12, 676458, 10.3389/fmicb.2021.676458 · DOI · Paper page
  152. Swartjes, 2013, A functional DNase I coating to prevent adhesion of bacteria and the formation of biofilm, Adv. Funct. Mater., 23, 2843, 10.1002/adfm.201202927 · DOI · Paper page
  153. Tahmassebi, 2015, A study of the control of oral plaque biofilms via antibacterial photodynamic therapy, Eur. Arch. Paediatr. Dent., 16, 433, 10.1007/s40368-014-0165-5 · DOI
  154. Talapko, 2020, The principles, mechanisms, and benefits of unconventional agents in the treatment of biofilm infection, Pharmaceuticals (Basel), 13, 299, 10.3390/ph13100299 · DOI
  155. Thi, 2020, Pseudomonas aeruginosa biofilms, Int. J. Mol. Sci., 21, 8671, 10.3390/ijms21228671 · DOI · Paper page
  156. Tovar-Garcia, 2020, Characterization of gallium resistance induced in a Pseudomonas aeruginosa cystic fibrosis isolate, Arch. Microbiol., 202, 617, 10.1007/s00203-019-01777-y · DOI
  157. Tummler, 2019, Emerging therapies against infections with Pseudomonas aeruginosa, F1000Res, 8, 1371, 10.12688/f1000research.19509.1 · DOI · Paper page
  158. Tuon, 2022, Pathogenesis of the Pseudomonas aeruginosa biofilm: A review, Pathogens, 11, 300, 10.3390/pathogens11030300 · DOI · Paper page
  159. Vuotto, 2019, Novel treatment strategies for biofilm-based infections, Drugs, 79, 1635, 10.1007/s40265-019-01184-z · DOI
  160. Wagner, 2016, Novel strategies for the treatment of Pseudomonas aeruginosa infections, J. Med. Chem., 59, 5929, 10.1021/acs.jmedchem.5b01698 · DOI · Paper page
  161. Wainwright, 2017, Photoantimicrobials-are we afraid of the light?, Lancet Infect. Dis., 17, e49, 10.1016/s1473-3099(16)30268-7 · DOI · Paper page
  162. Wang, 2019, Synergistic activity of Fosfomycin, ciprofloxacin, and gentamicin Against Escherichia coli and Pseudomonas aeruginosa biofilms, Front. Microbiol., 10, 2522, 10.3389/fmicb.2019.02522 · DOI
  163. Wang, 2022, Photocatalytic quantum dot-armed bacteriophage for combating drug-resistant bacterial infection, Adv. Sci. (Weinh), 9, e2105668, 10.1002/advs.202105668 · DOI
  164. Wang, 2020, Regulation of Pseudomonas aeruginosa biofilms by quorum sensing systems and c-di-GMP, Acta Microbiol. Sin., 61, 1106, 10.13343/j.cnki.wsxb.20200367 · doi:10.13343/j.cnki.wsxb.20200367
  165. Wang, 2015, The exopolysaccharide Psl-eDNA interaction enables the formation of a biofilm skeleton in Pseudomonas aeruginosa, Environ. Microbiol. Rep., 7, 330, 10.1111/1758-2229.12252 · DOI · Paper page
  166. Wang, 2021, An engineered bacterium for the targeted delivery of proteins to destroy Pseudomonas aeruginosa biofilms, Acta Microbiol. Sin., 61, 2726, 10.13343/j.cnki.wsxb.20200680 · doi:10.13343/j.cnki.wsxb.20200680
  167. Wei, 2013, Biofilm matrix and its regulation in Pseudomonas aeruginosa, Int. J. Mol. Sci., 14, 20983, 10.3390/ijms141020983 · DOI · Paper page
  168. Wen, 2013, Antibacterial and membrane-damaging activities of beta-bungarotoxin B chain, J. Pept. Sci., 19, 1, 10.1002/psc.2463 · doi:10.1002/psc.2463
  169. Whiteley, 2017, Progress in and promise of bacterial quorum sensing research, Nature, 551, 313, 10.1038/nature24624 · DOI · Paper page
  170. Wi, 2018, Understanding biofilms and novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections, Infect. Dis. Clin. N. Am., 32, 915, 10.1016/j.idc.2018.06.009 · DOI · Paper page
  171. Williams, 2019, Towards understanding the molecular basis of nitric oxide-regulated group behaviors in pathogenic bacteria, J. Innate Immun., 11, 205, 10.1159/000494740 · DOI
  172. Wilton, 2016, Extracellular DNA acidifies biofilms and induces aminoglycoside resistance in Pseudomonas aeruginosa, Antimicrob. Agents Chemother., 60, 544, 10.1128/AAC.01650-15 · DOI · Paper page
  173. Wu, 2021, Transcriptional profiling of Pseudomonas aeruginosa PAO1 in response to anti-biofilm and anti-infection agent exopolysaccharide EPS273, J. Appl. Microbiol., 130, 265, 10.1111/jam.14764 · DOI
  174. Xiu, 2021, Recent development of nanomedicine for the treatment of bacterial biofilm infections, Viewpoints, 2, 20200065, 10.1002/VIW.20200065 · DOI
  175. Yadav, 2021, Recent development in therapeutic strategies targeting Pseudomonas aeruginosa biofilms – a review, Mater. Today Proc., 46, 2359, 10.1016/j.matpr.2021.05.245 · DOI
  176. Yan, 2014, Bacteriophage polysaccharide depolymerases and biomedical applications, BioDrugs, 28, 265, 10.1007/s40259-013-0081-y · DOI · Paper page
  177. Yang, 2015, Nitric oxide based strategies for applications of biomedical devices, Biosurf. Biotribol., 1, 177, 10.1016/j.bsbt.2015.08.003 · DOI
  178. Yong, 2018, The microbial endocrinology of Pseudomonas aeruginosa: inflammatory and immune perspectives, Arch. Immunol. Ther. Exp., 66, 329, 10.1007/s00005-018-0510-1 · DOI
  179. Yu, 2019, Anti-bacterial activity of mutant chensinin-1 peptide against multidrug-resistant Pseudomonas aeruginosa and its effects on biofilm-associated gene expression, Exp. Ther. Med., 17, 2031, 10.3892/etm.2019.7182 · doi:10.3892/etm.2019.7182
  180. Yu, 2015, PslG, a self-produced glycosyl hydrolase, triggers biofilm disassembly by disrupting exopolysaccharide matrix, Cell Res., 25, 1352, 10.1038/cr.2015.129 · DOI · Paper page
  181. Zhang, 2018, Effects of PslG on the surface movement of Pseudomonas aeruginosa, Appl. Environ. Microbiol., 84, e00219-18, 10.1128/AEM.00219-18 · doi:10.1128/aem.00219-18
  182. Zhao, 2021, Glutamine promotes antibiotic uptake to kill multidrug-resistant uropathogenic bacteria, Sci. Transl. Med., 13, eabj0716, 10.1126/scitranslmed.abj0716 · DOI · Paper page
  183. Zhao, 2018, Extracellular aminopeptidase modulates biofilm development of Pseudomonas aeruginosa by affecting matrix exopolysaccharide and bacterial cell death, Environ. Microbiol. Rep., 10, 583, 10.1111/1758-2229.12682 · DOI
  184. Zhu, 2022, Slippery liquid-Like solid surfaces with promising antibiofilm performance under both static and flow conditions, ACS Appl. Mater. Interfaces, 14, 6307, 10.1021/acsami.1c14533 · doi:10.1021/acsami.1c14533
  185. Zhu, 2019, Nitric oxide and iron signaling cues have opposing effects on biofilm development in Pseudomonas aeruginosa, Appl. Environ. Microbiol., 85, e02175-18, 10.1128/AEM.02175-18 · DOI

Cited by

See all 151

Metadata

Authors
Yin, R., Cheng, J., Wang, J., Li, P., & Lin, J.
Venue
Frontiers in Microbiology
Published
2022-08-26
Volume
13
ISSN
1664-302X
Cited by
151
References
14

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.